MO-IPS suppresses acute myeloid leukemia through metabolic reprogramming and synergizes with anti-PD-1 immunotherapy. - Wang Y; Zhao W; Jin Y; Hu C; Fang X; Dong S; Zhang B (Functional & integrative genomics, 2026)